Compare NVAX & HTFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NVAX | HTFL |
|---|---|---|
| Founded | 1987 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.2B |
| IPO Year | 1996 | 2025 |
| Metric | NVAX | HTFL |
|---|---|---|
| Price | $10.90 | $51.93 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 9 |
| Target Price | $14.44 | ★ $50.50 |
| AVG Volume (30 Days) | ★ 6.8M | 1.5M |
| Earning Date | 11-05-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 309.76 | 82.37 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,123,479,000.00 | $176,034,000.00 |
| Revenue This Year | N/A | $41.24 |
| Revenue Next Year | N/A | $24.11 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 64.69 | 39.92 |
| 52 Week Low | $6.20 | $20.13 |
| 52 Week High | $13.39 | $60.56 |
| Indicator | NVAX | HTFL |
|---|---|---|
| Relative Strength Index (RSI) | 52.16 | 45.82 |
| Support Level | $7.93 | $46.46 |
| Resistance Level | $11.73 | $52.38 |
| Average True Range (ATR) | 0.79 | 3.22 |
| MACD | -0.05 | -0.74 |
| Stochastic Oscillator | 70.99 | 5.02 |
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
HeartFlow Inc is a commercial-stage medical technology company that provides software and artificial intelligence (AI) designed to deliver a non-invasive solution for diagnosing and managing coronary artery disease. The company operates and manages its business as a single reportable operating segment: non-invasive coronary artery disease detection solutions. Geographically, it operates in the United States and the rest of Europe, deriving the majority of its revenue from the United States. The company has developed three software products: Heartflow Roadmap Analysis, Heartflow FFRCT Analysis, and Heartflow Plaque Analysis.